tbuckley/cabot-search huggingface dataset:
Abstract B34: Inhibitor of DNA binding (Id) regulates glioma infiltration on myelin tracts by suppressing Nogo receptor 1
Authors: JunHee Hong, Young Taek Oh, Tae Hoon Kim, Jong Bae Park
Journal: Cancer Research (2017)

Abstract Myelin-associated infiltration is mostly attributed to clinical failure of glioma. Identifying molecular mechanisms and identity of infiltrating cells are major concern in glioma research. Here, we show that stem cell properties of glioma contribute to myelin-associated infiltration by the down-regulation of NgR1, a receptor for myelin-associated inhibitors (MAIs). Inhibitors of DNA binding (Id) proteins, regulators of early neural development, are responsible for down-regulation of NgR1. During differentiation and dedifferentiation of glioma stem cells (GSCs) Id/NgR1 regulation was reversible, and correlated to the infiltrative capacity of GSCs. Remarkably, NgR1 overexpression in mouse xenograft blocks infiltration of GSCs on myelin and significantly increased survival. NgR1 and Id1/4 levels are inversely correlated and low expression of NgR1 portends poor prognosis in glioma patients. Our findings clarify that functional significance of NgR1 regulation and provide first molecular evidence for myelin-associated infiltration. Our work suggests Id-NgR1 axis as a novel prognostic marker and proposes this axis as a potential targets for future therapeutic intervention for the myelin-associated glioma infiltration. Citation Format: JunHee Hong, Young Taek Oh, Tae Hoon Kim, Jong Bae Park. Inhibitor of DNA binding (Id) regulates glioma infiltration on myelin tracts by suppressing Nogo receptor 1. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr B34.
B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb
Authors: Xinxin Nie, Wenni Chen, Ying Zhu, Baozhu Huang, Weiwei Yu, Zhanshuai Wu, Sizheng Guo, Yiping Zhu, Liqun Luo, Shengdian Wang, Lieping Chen
Journal: Cellular and Molecular Immunology (2017)
HOXB-AS3 Regulates Cell Cycle Progression and Interacts with the Drosophila Splicing Human Behavior (DSHB) Complex in NPM1-Mutated Acute Myeloid Leukemia
Authors: Dimitrios Papaioannou, Andreas Petri, Charlotte Albæk Thrue, Stefano Volinia, Karl Kroll, Yan Pearlly, Ralf Bundschuh, Guramrit Singh, Sakari Kauppinen, Clara D. Bloomfield, Adrienne Dorrance, Ramiro Garzon
Journal: Blood (2016)
Abstract A11: Profiling of miRNAs expression in pediatric brain tumors
Authors: Marwa Tantawy, Mariam Elzayat, Dina Yehia, Hala Taha
Journal: Cancer Research (2017)

Abstract Introduction: The understanding of pediatric CNS tumors biology is essential in the development of disease stratification and in development of less toxic therapeutic agents as well as finding novel markers for early diagnosis. MicroRNAs are short 18-25 nucleotide small non-coding RNA molecules regulate gene expression. Recent studies showed that miRNAs play a significant role in brain tumor biology; and may up-regulated or down-regulated in malignancies, which referred their oncogenic or tumor suppressor effect. MiRNA expression patterns have been linked to clinical outcomes, tumor regulation; such as tumor progression, cell growth, cell death and metastasis. The identification of tumor- specific miRNA signatures may assist in future in the discovery of new biomarkers with diagnostic and prognostic utility. The main objective of the present study is to detect the expression of different miRNAs in different subtypes of pediatric CNS tumors to distinguish between them in discovering biomarkers for early detection in addition to develop novel therapies. Methods: The expression level of 82 miRNAs were detected in 120 cases of pediatric CNS tumors from fixed formalin paraffin embedded tissues (FFPE), divided into four subtypes including; Low Grade Glioma, High Grade Glioma, Ependymoma, and Medulloblastoma using quantitative real time PCR (qRTPCR). Results: Analysis of qRT-PCR data showed significant differences in miRNA expression between tumor subtypes with P value&amp;lt; 0.05. Low expression of (miR-221, miR-9, and miR-181c/d) and over expression in miR-101, miR-222, miR-139, miR-1827 and miR-34c) in Medulloblastoma patients compared to other subtypes. Low expression of miR-10a and overexpression in (miR-10b, and miR-29a) in Ependymoma patients compared to other subtypes. Low expression of miR-26a and over expression in (miR-19a/b, miR-24, miR-27a, miR- 584 and miR-527) in Low Grade Glioma patients compared to other subtypes. Conclusion: MicroRNAs are differentially expressed between different subtypes of pediatric CNS tumors suggesting that they may play a significant role in diagnosis to distinguish between different subtypes. A greater understanding of aberrant miRNA expression in pediatric brain tumors may support in the development of novel therapies. In addition, the characterization of tumor-specific miRNA signatures may play an important role in the discovery of biomarkers with diagnostic or prognostic utility. Note: This abstract was not presented at the conference. Citation Format: Marwa Tantawy, Mariam Elzayat, Dina Yehia, Hala Taha. Profiling of miRNAs expression in pediatric brain tumors. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr A11.
Combination of an ASK1 inhibitor and FXR agonist increases efficacy in a mouse model of non-alcoholic steatohepatitis
Authors: J.T. Liles, A. Zagorska, D. Hollenback, G.R. Budas, H. Liu, K. Liu, R. Brockett, A. Shauf, D. Tumas, D.G. Breckenridge
Journal: Journal of Hepatology (2017)
AKT inhibitor ARQ 092 and sorafenib additively inhibit progression of hepatocellular carcinoma and improve immune system in cirrhotic rat model
Authors: Z.M. Jilkova, A.Z. Kuyucu, K. Kurma, S.T.A. Pour, G.S. Roth, G. Abbadessa, Y. Yu, V. Leroy, P. Marche, T. Decaens
Journal: Journal of Hepatology (2017)
An exploratory study to evaluate immune restoration after removal of viral antigen in adults with genotype 1a chronic hepatitis C virus infection treated with ombitasvir/oparitaprevir/ritonavir + dasabuvir and ribavirin for 12 weeks
Authors: C. Carlton-Smith, J.A. Holmes, A.Y. Kim, E.O. Dumas, J. Brown, N. Alatrakchi, G.M. Lauer, S.T. Silva, P. Tonnerre, D.E. Cohen, H. Zhang, N.S. Shulman, R.T. Chung
Journal: Journal of Hepatology (2017)
Note on the Discovery of the Human Trypanosome
Authors: R. Boyce, R. Ross, C. S. Sherrington
Journal: BMJ (1902)

WE have recently seen in the medical Press several very inaccurate accounts regarding the authorship of the important new discovery of trypanosomes in human blood, and of the disease caused by them. For instance, the Journal of Tropical Medicine for November I (in giving an anonymous description, supported by an editorial, of a case just observed by Drs. Daniels and Manson) attributes the original discovery to Dr. R. M. Forde. It does not mention even the name of Dr. J. Everett Dutton. Dr. Dutton is an old student and assistant in this Laboratory, and is now away on the West African Coast; and we are of opinion that he has a claim to be considered in the matter of this discovery. Another periodical, The Hospital for November 8, while also omitting Dr. Dutton's name, states that the discovery was made “within the last few days” by the London School of Tropical Medicine. We believe that such statements are calculated to distort the history of the discovery, and should therefore like to have an opportunity for correcting them promptly in your pages.
The role of dysbiosis in the development of non-alcoholic fatty liver disease in obese patients
Authors: E. Nistal, S. Sanchez-Campos, M.V. García-Mediavilla, M.T. Arias, P. Linares, P. Iruzubieta, B. Álvarez, J.M.G. Lobo, J.L. Olcoz, J. Crespo, F. Jorquera
Journal: Journal of Hepatology (2017)
ACC/AHA 2008 Statement on Performance Measurement and Reperfusion Therapy
Authors: Frederick A. Masoudi, Robert O. Bonow, Ralph G. Brindis, Christopher P. Cannon, Jo DeBuhr, Susan Fitzgerald, Paul A. Heidenreich, Kalon K.L. Ho, Harlan M. Krumholz, Chris Leber, David J. Magid, David S. Nilasena, John S. Rumsfeld, Sidney C. Smith, Thomas P. Wharton
Journal: Journal of the American College of Cardiology (2008)
Pretransplant glycomic analysis of perfusate is predictive of primary non function after liver transplantation
Authors: X. Verhelst, A. Geerts, D. Vanderschaeghe, X. Rogiers, A. Vanlander, F. Berrevoet, N. Callewaert, R.I. Troisi, H. Van Vlierberghe
Journal: Journal of Hepatology (2017)
Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies
Authors: V.C. Di Maio, V. Cento, I. Lenci, M. Aragri, S. Barbaliscia, S. Francioso, S. Paolucci, M. Melis, G. Verucchi, N. Coppola, C.F. Magni, V. Micheli, T. Pollicino, T. Ruggiero, F. Santopaolo, S. Landonio, A. Mancon, M. Starace, A. Bertoli, F.P. Antonucci, C. D’Ambrosio, V. Calvaruso, F. Morisco, C. Pasquazzi, I. Maida, A. Picciotto, A.D. Biagio, B. Bruzzone, L. Sticchi, V. Ghisetti, R. Cozzolongo, D. Romagnoli, V. Boccaccio, A. Grieco, J. Vecchiet, G. D’Ettorre, M. Merli, G.B. Gaeta, A. Ciancio, L. Marinaro, P. Andreone, G. Barbarini, R. Gulminetti, V.P. Palitti, P. Tarquini, M. Puoti, V. Sangiovanni, G.D. Stefano, A. Giorgini, M. Paoloni, N. Caporaso, S. Babudieri, G. Gubertini, S. Bruno, M. Andreoni, A. Pellicelli, G. Parruti, G. Raimondo, F. Baldanti, A. Craxì, M. Angelico, C.F. Perno, F. Ceccherini-Silberstein
Journal: Journal of Hepatology (2017)
Non-Organ-Specific Autoantibodies and BKV Infection in renal transplant recipients.
Authors: F. Giacchino, C. Costa, G.A. Touscoz, C. Merlino, M. Bergallo, G.P. Segoloni, F. Bonello, P. Belardi, R. Cavallo
Journal: Journal of the American Society of Nephrology (2005)
Prognostic value of pre- to post-treatment primary tumor metabolic volume reduction on 18F-FDG-PET/CT in a patient cohort with inoperable locally-advanced NSCLC treated with definitive chemoradiotherapy
Authors: O. Roengvoraphoj, C. Eze, W. Fendler, M. Dantes, C. Belka, F. Manapov
Journal: Annals of Oncology (2017)
Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism
Authors: Rodolfo Savica, Brandon R. Grossardt, James H. Bower, J. Eric Ahlskog, Bradley F. Boeve, Jonathan Graff-Radford, Walter A. Rocca, Michelle M. Mielke
Journal: JAMA Neurology (2017)

To our knowledge, a comprehensive study of the survival and causes of death of persons with synucleinopathies compared with the general population has not been conducted. Understanding the long-term outcomes of these conditions may inform patients and caregivers of the expected disease duration and may help with care planning.To compare survival rates and causes of death among patients with incident, clinically diagnosed synucleinopathies and age- and sex-matched referent participants.This population-based study used the Rochester Epidemiology Project medical records-linkage system to identify all residents in Olmsted County, Minnesota, who received a diagnostic code of parkinsonism from 1991 through 2010. A movement-disorders specialist reviewed the medical records of each individual to confirm the presence of parkinsonism and determine the type of synucleinopathy. For each confirmed patient, an age- and sex-matched Olmsted County resident without parkinsonism was also identified.We determined the age- and sex-adjusted risk of death for each type of synucleinopathy, the median time from diagnosis to death, and the causes of death.Of the 461 patients with synucleinopathies, 279 (60.5%) were men, and of the 452 referent participants, 272 (60.2%) were men. From 1991 through 2010, 461 individuals received a diagnosis of a synucleinopathy (309 [67%] of Parkinson disease, 81 [17.6%] of dementia with Lewy bodies, 55 [11.9%] of Parkinson disease dementia, and 16 [3.5%] of multiple system atrophy with parkinsonism). During follow-up, 68.6% (n = 316) of the patients with synucleinopathies and 48.7% (n = 220) of the referent participants died. Patients with any synucleinopathy died a median of 2 years earlier than referent participants. Patients with multiple system atrophy with parkinsonism (hazard ratio, 10.51; 95% CI, 2.92-37.82) had the highest risk of death compared with referent participants, followed by those with dementia with Lewy bodies (hazard ratio, 3.94; 95% CI, 2.61-5.94), Parkinson disease with dementia (hazard ratio, 3.86; 95% CI, 2.36-6.30), and Parkinson disease (hazard ratio, 1.75; 95% CI, 1.39-2.21). Neurodegenerative disease was the most frequent cause of death listed on the death certificate for patients, and cardiovascular disease was the most frequent cause of death among referent participants.Individuals with multiple system atrophy with parkinsonism, dementia with Lewy bodies, and Parkinson disease dementia have increased mortality compared with the general population. The mortality among persons with Parkinson disease is only moderately increased compared with the general population.
Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab
Authors: Patrick Grossmann, Vivek Narayan, Ken Chang, Rifaquat Rahman, Lauren Abrey, David A Reardon, Lawrence H Schwartz, Patrick Y Wen, Brian M Alexander, Raymond Huang, Hugo J W L Aerts
Journal: Neuro-Oncology (2017)

Anti-angiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic strategies on the basis of MRI have the potential to noninvasively stratify survival and progression in this patient population. In an initial cohort of 126 patients, we identified a distinct set of features representative of the radiographic phenotype on baseline (pretreatment) MRI. These selected features were evaluated on a second cohort of 165 patients from the multicenter BRAIN trial with prospectively acquired clinical and imaging data. Features were evaluated in terms of prognostic value for overall survival (OS), progression-free survival (PFS), and progression within 3, 6, and 9 months using baseline imaging and first follow-up imaging at 6 weeks posttreatment initiation. Multivariable analysis of features derived at baseline imaging resulted in significant stratification of OS (hazard ratio [HR] = 2.5; log-rank P = 0.001) and PFS (HR = 4.5; log-rank P = 2.1 × 10−5) in validation data. These stratifications were stronger compared with clinical or volumetric covariates (permutation test false discovery rate [FDR] <0.05). Univariable analysis of a prognostic textural heterogeneity feature (information correlation) derived from postcontrast T1-weighted imaging revealed significantly higher scores for patients who progressed within 3 months (Wilcoxon test P = 8.8 × 10−8). Generally, features derived from postcontrast T1-weighted imaging yielded higher prognostic power compared with precontrast enhancing T2-weighted imaging. Radiomics provides prognostic value for survival and progression in patients with recurrent glioblastoma receiving bevacizumab treatment. These results could lead to the development of quantitative pretreatment biomarkers to predict benefit from bevacizumab using standard of care imaging.
Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding
Authors: Qiuhe Wang, Yong Lv, Ming Bai, Zhengyu Wang, Haibo Liu, Chuangye He, Jing Niu, Wengang Guo, Bohan Luo, Zhanxin Yin, Wei Bai, Hui Chen, Enxin Wang, Dongdong Xia, Xiaomei Li, Jie Yuan, Na Han, Hongwei Cai, Tao Li, Huahong Xie, Jielai Xia, Jianhong Wang, Hongbo Zhang, Kaichun Wu, Daiming Fan, Guohong Han
Journal: Journal of Hepatology (2017)
Nutritional habits in patients with chronic liver disease: adherence of real life diet to international guidelines and its association with disease stage
Authors: E. Poli, S. Carnevale, F. Miceli, F. Ferri, M. Mischitelli, L. Parlati, S. Parisse, M. Lupo, A. Pintore, F. Di Bartolomeo, A. De Santis, S.G. Corradini
Journal: Journal of Hepatology (2017)
Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcohol related liver disease in the United States between 2005 and 2013
Authors: A.L. Nguyen, P. Nguyen, D. Jeong, J.K. Hoang, E. Sheen, Y.A. Kim, H. Park, M.H. Nguyen
Journal: Journal of Hepatology (2017)
Heterozygous carriage of the alpha1-antitrypsin Z variant rs28929474 predisposes to the development of cirrhosis in the presence of alcohol misuse and non-alcohol-related fatty liver disease
Authors: P. Strnad, S. Buch, K. Hamesch, J. Rosendahl, J. Fischer, H.-D. Nischalke, I. Spivak, S. Janciauskiene, M. Mandorfer, M. Trauner, B. Sipos, C. Schafmayer, E. Aigner, C. Datz, F. Stickel, M.Y. Morgan, J. Hampe, C. Trautwein, T. Berg
Journal: Journal of Hepatology (2017)
Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN
Authors: R. D’ambrosio, A. Aghemo, E. Degasperi, A. Sangiovanni, M. Rumi, M. Fraquelli, R. Perbellini, P. Bedossa, M. Colombo, P. Lampertico
Journal: Journal of Hepatology (2017)
Leptomeningeal metastases in high-grade glioma: A series of 41 cases.
Authors: Christopher John Dardis, Lynn Stuart Ashby, Kelly Milton, William R. Shapiro
Journal: Journal of Clinical Oncology (2014)

e13024 Background: No treatment guidelines currently exist for management of leptomeningeal spread (LMD) from glial tumors.This is the largest case series to date addressing this topic. In cases where LMD is present at time of diagnosis, a strong case has already been made for use of radiation and temozolomide. Regarding intrathecal chemotherapy, one prior case series noted promising results with thioTEPA and one case report with liposomal cytarabine; another suggested Palliative care may be preferable in general. Methods: We sought to characterize all such cases in our institution over the preceding 10 years. This was done by retrospective review of the records of our weekly Multidisciplinary Conference from 2003-2013 (n = c. 12,000) for cases of leptomeningeal spread due to high-grade glial tumors. Descriptive statistics were calculated and Cox's proportional hazards models used to determine important predictors of time to progrsesion and overall survival following diagnosis of LMD. Results: Of the 41 cases identified, leptomeningeal spread was present at the time of diagnosis in 5 patients. Of the remaining 35 with information available, leptomeningeal spread occurred at the time of first progression in 18. Median time to further progression following diagnosis was 5.0 months (range 0.8 - 62.8). In the 38 with follow-up available (26 confirmed deaths) the median survival was 9.9 months (95% CI 8.8-19). Use of systemic chemotherapy following diagnosis of LMD predicted increased time to progression (median 5.4 vs 1.6 months, p=0.02); use of radiation therapy increased overall survival (18.9 vs 7.4 months, p=0.04). Karnofsky Permance Status of >= 70 at time of diagnosis predicted increased time to progression and overall survival (6.9 vs 3.1, p=0.007 and 19 vs 7.4, p=0.08). In bivariable models this accounted for a more accurate predicton of outcome than either of the above treatments. No benefit could be shown with use of intrathecal chemotherapy in 8 patients, although half had shunts placed which may have lead to reduced efficacy. Conclusions: Treatment for this rare complication should be individualized and will depend in large part on performace status. Systemic chemotherapy and focal radiation appear reasonable.
Abstract IA30: Targeting hormone receptors for degradation: Nuclear receptor downregulation as a therapeutic approach in cancer
Authors: Donald McDonnell, Kimberly Cocce, Suzanne Wardell, John Norris
Journal: Clinical Cancer Research (2017)

Abstract Durable clinical responses to endocrine therapies in breast cancer are limited by the development of resistance that can occur as a consequence of estrogen receptor–alpha (ERα) mutations, the production of non-canonical ER ligands, or to the reprogramming of ER signaling pathways. This contemporary view of resistance has driven the search for Selective Estrogen Receptor Degraders (SERDs), compounds that target the receptor for proteasomal degradation. The clinical activity of fulvestrant, the first drug in this class, confirmed the utility of SERDs in late stage disease; however the poor pharmaceutical properties of this drug have limited its use. Previously, we reported the discovery and early clinical development of the first orally bioavailable SERD (GW5638) and although its development was discontinued, the early positive signals from clinical studies of this drug provided others with the impetus to develop additional molecules that function using the same mechanism of action (GDC810 and AZ9694). These latter drugs, if approved, will be significant additions to the breast cancer armamentarium. Anticipating that acquired resistance is likely to be a response to SERD treatment, we have recently embarked on an effort to identify targets/pathways that are required for the maintenance of the receptor expression. It is anticipated that combined treatment with SERDs and agents that inhibit ERα expression would result in more durable clinical responses. These efforts have led to the discovery that the AGR2/LYPD3 signaling axis within cancer cells is required for ERα expression and that its inhibition achieves a quantitative downregulation of this receptor in tumor models. The impact of targeting ERα expression, directly (SERDs) and/or indirectly (AGR2 blocking antibodies) in breast cancer will be the focus of this presentation. Citation Format: Donald McDonnell, Kimberly Cocce, Suzanne Wardell, John Norris. Targeting hormone receptors for degradation: Nuclear receptor downregulation as a therapeutic approach in cancer. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr IA30.